Aurora2 is a cell cycle regulated serine/threonine protein kinase which is overexpressed in many tumor cell lines. We demonstrate that Aurora2 is regulated by phosphorylation in a cell cycle dependent manner. This phosphorylation occurs on a conserved residue, Threonine 288, within the activation loop of the catalytic domain of the kinase and results in a signi®cant increase in the enzymatic activity. Threonine 288 resides within a consensus motif for the cAMP dependent kinase and can be phosphorylated by PKA in vitro. The protein phosphatase 1 is shown to dephosphorylate this site in vitro, and in vivo the phosphorylation of T288 is induced by okadaic acid treatment. Furthermore, we show that the Aurora2 kinase is regulated by proteasome dependent degradation and that Aurora2 phosphorylated on T288 may be targeted for degradation during mitosis. Our experiments suggest that phosphorylation of T288 is important for regulation of the Aurora2 kinase both for its activity and its stability. Oncogene (2000) 19, 4906 ± 4916.
Introduction
Accurate chromosome segregation during mitosis is a crucial step for normal cell division. Chromosome segregation depends on proper spindle assembly followed by attachment of the microtubules to the kinetochores of the chromosomes. Failure to form a bipolar spindle or to attach the chromosomes to the spindle activates the mitotic checkpoint to arrest the cells at the onset of anaphase (reviewed in Hardwick, 1998) . The mechanisms by which checkpoint controls are triggered during mitosis are only poorly understood but result in the inhibition of the anaphase-promoting complex (APC). The APC is a multimeric ubiquitin ligase that mediates destruction box dependent ubiquitination of proteins, which are subsequently targeted for degradation by the proteasome (reviewed in Morgan, 1999; Page and Hieter, 1997) . Defects in checkpoint control can result in abnormal chromosome number (aneuploidy), a phenomenon often observed in tumor cells (Orr-Weaver and Weinberg, 1998) .
In addition to regulation by degradation, checkpoint controls and other mitotic events are tightly regulated by phosphorylation and dephosphorylation events. The requirement of Cdc2/cyclin B activity to enter mitosis has been well established (Nurse, 1990) but in recent years novel kinases have been identi®ed providing more insight into the complex regulation of mitosis. The Polo-like kinases have been described as regulating multiple stages of mitosis (reviewed in Nigg, 1998; Glover et al., 1998) . They are involved in activation of Cdc2/cyclin B early in mitosis but are also required for exit of mitosis by activation of the APC. Second, the NimA-related kinases are reported to play a role in centrosome separation (Mayor et al., 1999) . Localized at the kinetochores members of the Bub1 kinase family are involved in spindle checkpoint regulation during mitosis (Straight, 1997) . Recently a new family of Aurora/Ipl1-related kinases has been shown to be involved in regulating spindle formation and chromosome segregation in various organisms (reviewed in Giet and Prigent, 1999; Bischo and Plowman, 1999) .
In a screen for temperature-sensitive conditional mutants for chromosomal missegregation in Saccharomyces cerevisiae, Ipl1 (for increase in ploidy 1) was identi®ed (Chan and Botstein, 1993) . At the restrictive temperature, mutations in Ipl1 result in chromosome missegregation but have no eect on bipolar spindle formation (Francisco et al., 1994) . Interestingly, the Ipl1 kinase was shown in vitro to phosphorylate Ndc10p, a component of the kinetochore CBF3 protein complex, suggesting a role of Ipl1 in kinetochore function (Biggins et al., 1999) . In Drosophila melanogaster mutations of the aurora allele result in pupal lethality and mitotic arrest. The arrested cells show circular monopolar spindles around large centrosomes indicating that Aurora is involved in centrosome separation and bipolar spindle formation (Glover et al., 1995) . A member of the Aurora/Ipl1-related kinase family in Xenopus laevis, pEg2, is reported to associate with the spindle poles and the mitotic spindle. Furthermore pEg2 activity is required for bipolar spindle assembly in Xenopus egg extracts (Roghi et al., 1998) . In Caenorhabditis elegans two Aurora/Ipl1 family members are identi®ed, AIR-1 and AIR-2. RNA mediated interference experiments revealed that AIR-1 is required for proper spindle organization (Schumacher et al., 1998a) , while the AIR-2 kinase is necessary for cytokinesis (Schumacher et al., 1998b) .
In mammals, there are three family members described so far. The human Aurora1/AIK2 (Bischo et al., 1998) , which is the homolog to AIM-1 in rat (Terada et al., 1998) , and ARK2 or STK-1 in mouse (Shindo et al., 1998) , localizes to the midbody during telophase and cytokinesis suggesting a function of Aurora1 later in mitosis. Over-expression of kinase inactive AIM-1 disrupts the cleavage furrow formation resulting in frequent failure of cytokinesis and aneuploidy (Terada et al., 1998) . As second family member Aurora2/AIK/BTAK/STK15 in human (Bischo et al., 1998; Sen et al., 1997; Kimura et al., 1997) , and IAK1/Ayk1 in mouse (Gopalan et al., 1997; Yanai et al., 1997) localizes to the centrosomes and the mitotic spindle and was shown to be involved in tumorigenesis. Human Aurora2 is reported to be ampli®ed and over-expressed in various tumor cell lines and in 12% of primary breast tumors and more than 50% of primary colorectal cancers (Bischo et al., 1998; Zhou et al., 1998) . Aurora2 is localized on chromosome 20q13, a region commonly ampli®ed in breast cancers correlated with poor prognosis (Sen et al., 1997) . Overexpression of Aurora2/STK15 in NIH3T3 cells results in abnormal centrosome numbers and transformation of the cells (Zhou et al., 1998) . A third family member, Aik3/AIE2, is localized at the centrosome only in anaphase and expression levels of Aik3 are elevated in several cancer cell lines (Kimura et al., 1997; Bernard et al., 1998; Tseng et al., 1998) . Thus, there is compelling evidence that the Aurora/Ipl1 family of serine/threonine kinases are important regulators of mitosis. However, the mechanisms, by which the expression and activity of these kinases is regulated, have not been elucidated.
In this study we provide evidence that the Aurora2 kinase is regulated by phosphorylation and degradation during the cell cycle. We observe that okadaic acid treatment results in phosphorylation of Threonine 288 in Aurora2 which is accompanied by an increase in kinase activity. We demonstrate that the cAMP dependent kinase speci®cally phosphorylates T288 of Aurora2 in vitro resulting in an increase of the speci®c kinase activity while the protein phosphatase 1 is able to dephosphorylate this residue. Furthermore, we show that the Aurora2 kinase is ubiquitinated and degraded in a proteasome-dependent manner during mitosis
Results

Okadaic acid treatment induces phosphorylation of Aurora2 on Thr288
To understand regulation of the Aurora2 kinase during mitosis, we wanted to explore the possibility that Aurora2 is regulated by phosphorylation. Previously Eg2, which is a member of the Aurora/Ipl1 family of serine/threonine kinases in Xenopus, was described to be phosphorylated and activated by okadaic acid treatment (Andresson and Ruderman, 1998) . Okadaic acid is a potent inhibitor of serine/threonine phosphatases suggesting that phosphorylation might be involved in regulation of the Eg2 kinase. To investigate whether okadaic acid treatment aects human Aurora2 activity, we treated HeLa cells with increasing concentrations of okadaic acid and performed in vitro kinase assays with immunoprecipitated Aurora2 (Figure 1a) . We observed that the Aurora2 kinase activity was increased twofold by okadaic acid treatment whilst the expression level of the Aurora2 kinase remained largely unaltered. Interestingly, a high concentration of okadaic acid was needed to aect Aurora2 activity. At this concentration okadaic acid inhibits both protein phosphatases PP2A and PP1 together, while at lower concentrations only PP2A would be inhibited (Takai et al., 1992) .
Having established that the human Aurora2 kinase activity is aected by phosphorylation, we next wanted to investigate what residues in Aurora2 were being modi®ed. No kinases have been identi®ed to phosphorylate Aurora/Ipl1 kinase family members to date. By examination of the Aurora2 cDNA sequence the threonine at residue 288 in the catalytic domain was found to be highly conserved in all Aurora family members as well as in various other serine/threonine kinases (Figure 1b) . This threonine residue is localized in the activation loop between the subdomains VII and VIII in the catalytic domain. A T288D mutant of Aurora2 was described previously to be activating and transforming in NIH3T3 ®broblasts (Bischo et al., 1998) . To study the potential of phosphorylation at this residue we generated polyclonal antibodies directed against phosphorylated T288. Western blot analysis was performed using SF9 cells overexpressing wild-type or mutant forms of Aurora2 treated with or without okadaic acid (Figure 1c ). We observed a dramatic increase in phosphorylation of T288 of wild-type Aurora2 expressed in SF9 cells after okadaic acid treatment accompanied by a shift in mobility of the phosphorylated forms of Aurora2. The forms of Aurora2 containing a mutation of T288 to aspartic acid or to alanine were not detected by the pT288 antibody. To further test speci®city of our antibodies we treated wild-type Aurora2 expressing SF9 cells with or without okadaic acid. The antibodies Aur2 and pT288 that were used to detect the proteins in immunoblot analysis were preincubated with or without the peptide that was used initially to immunize the rabbits. Both antibodies were blocked entirely in the presence of their peptides (Figure 1d ). Thus, we have identi®ed a phosphorylation site aected by okadaic acid treatment. We have shown for the ®rst time that okadaic acid treatment results in phosphorylation of T288.
In order to analyse more directly the impact of phosphorylation of T288 on Aurora2 kinase activity, various mutants were generated in baculovirus and expressed in SF9 cells. The threonine 288 residue was mutated to aspartic acid (T288D), a mutation designed to mimic phosphorylation, or mutated to alanine (T288A) to abolish phosphorylation. In vitro kinase assays using equivalent amounts of puri®ed recombinant enzyme, demonstrated a 6 ± 7-fold increase in the speci®c kinase activity of the T288D mutant ( Figure  2a) . Surprisingly, mutation of T288 to alanine was also active. Reanalysis of the Aurora2 sequence revealed an additional threonine residue at position 287. To address whether T287 was compensating for T288A as a phosphorylation site mediating activation, we generated a T287A/T288A double mutant. This mutant had reduced kinase activity, comparable to wild-type enzyme, providing evidence for this compensatory model (Figure 2a ). For each kinase assay the activities were corrected for the concentration of the recombinant Aurora proteins as determined in parallel by ECF immunoblot analyses. In addition, we examined if okadaic acid treatment can further activate the baculovirus expressed mutant forms of Aurora2 because the data presented in Figure 1 do not exclude the possibility of okadaic acid induced phosphorylation at other sites which could aect kinase activity. In vitro kinase assays, performed as described above, revealed that okadaic acid treatment has an eect on baculovirus expressed Aurora2 in SF9 cells. We observed a 14-fold increase in kinase activity of the wild-type form of Aurora2, while the activity of the T288D, the T288A and the T287A/T288A mutant forms of Aurora2 appeared to be aected only marginally. These results suggest that phosphorylation in the activation loop of the Aurora2 kinase is a prerequisite for activation ( Figure 2b ) and further demonstrate that phosphorylation of T288 is a key step in the activation of Aurora2 by okadaic acid treatment. Wild-type Aurora2 treated with okadaic acid is somewhat more active than the T288D mutant (see Figure  2a) suggesting that other modi®cations may further modulate Aurora2 kinase activity.
PKA phosphorylates Aurora2 on Thr288 in vitro
In Aurora2 the T288 residue falls within a consensus protein kinase A phosphorylation motif, RRXT, making PKA a good candidate for the kinase responsible for phosphorylation of Aurora2 in vivo (see Figure 1b) . To determine whether Aurora2 is a substrate of PKA we performed in vitro kinase assays using puri®ed PKA and as controls PKC, Cdc2 and ERK2 enzymes. The GST-Aurora2 fusion proteins used as substrates in these experiments were either a catalytically inactive form of Aurora2, K161M, to preclude the possibility of autophosphorylation (Figure 3a, lanes 1, 3, 5, 7) , or the double mutant K161M/T288D, which in addition to being catalytically inactive has T288 mutated to aspartic acid ( Figure 3a , lanes 2, 4, 6, 8). We detected radiolabeled The threonine residue T288 in Aurora2, which is the equivalent of Cdk2 T160, is indicated by an asterisk. (c) SF9 cells infected with wild-type and mutated forms of Aurora2 baculovirus were incubated with or without 500 nM okadaic acid for 1 h prior to harvest. Equal amounts of puri®ed baculovirus expressed Aurora2 protein were used in immunoblots with the T288 phospho-speci®c antibody (upper panel) or with the C-terminal Aurora2 antibody (lower panel). (d) The antibodies Aur2 and pT288 were preincubated in blocking solution with or without the speci®c peptides that were originally used for immunization. Immunoblot analyses were performed to detect wild-type Aurora2 protein that was isolated from SF9 cells infected with wild-type Aurora2 baculovirus and treated with or without okadaic acid as described above GST-Aurora2 in kinase reactions with PKA and PKC but not using either Cdc2 or Erk2 ( Figure 3a , upper panel). Thus, the Aurora2 kinase is selectively a substrate of PKA and PKC in vitro. Analysis of the Aurora2 cDNA sequence revealed several potential PKC sites and a second potential PKA phosphorylation site at S342, which may account for the low level of phosphorylation seen in lane 2. Performing an immunoblot using the phosphoT288 speci®c antibody with non-radioactive kinase reactions under the same conditions revealed that only PKA phosphorylates Aurora2 on T288 ( Figure 3a , middle panel, lane 1), while the double mutant GST-2-KM-TD is not recognized by the phosphoT288 speci®c antibody ( Figure 3a , lane 2). PKC, although it can phosphorylate Aurora2, does not phosphorylate T288 in vitro.
The protein levels of the GST-Aurora2 fusion proteins were similar in each kinase reaction as demonstrated by the anti-Aurora2 immunoblot ( Figure 3a , lower panel). These data show that Aurora2 is an in vitro substrate for both PKA and PKC and further establishes that the T288 residue in the catalytic domain of Aurora2 is a phosphorylation site of PKA in vitro.
We next wanted to address whether T288 phosphorylation by PKA aected Aurora2 kinase activity. To test this, we incubated puri®ed wild-type Aurora2 protein ( Figure 3b , lanes 1, 2), a mutant form of Aurora2 carrying a T287A/T288A double mutation (lanes 3, 4) or no protein as control (lanes 5, 6) with (lanes 2, 4, 6) or without PKA (lanes 1, 3, 5) and performed Western blot analyses (Figure 3b ). Phosphorylation of T288 of the wild-type form but not the double TA mutant form of Aurora2 was demonstrated by anti-pT288 Western blot analysis (Figure 3b , middle panel) while the input of Aurora2 protein was the same in each reaction (Figure 3b, upper panel) . Phosphorylation of T288 occurs concomitantly with a sixfold increase in kinase activity as shown by an in vitro kinase assay using MBP as substrate (Figure 3b, lower panel) . No induction of kinase activity over background can be observed in the mutant form of Aurora2 lacking T287/T288 providing further evidence that phosphorylation of T288 directly aects kinase activity. Given the background in these reactions we tested for PKA remaining in the Aurora2 immunprecipitations after washing (Figure 3b , bottom panel). By Western blot analysis with a PKA speci®c antibody, we did not observe more PKA protein in the reaction containing wild-type Aurora2 compared to the other reactions. Therefore, the dierence in MBP phosphorylation is not due to remaining PKA in the reactions. To further exclude the possibility of PKA aecting the kinase assays we performed the same experiment in the presence or absence of PKA-Inhibitor and performed Aurora2 in vitro kinase assays (Figure 3c ). Even in the presence of the PKA-Inhibitor we observed an induction of Aurora2 kinase activity of 3.4-fold. Therefore, we demonstrated that phosphorylation of Aurora2 on T288 by PKA concomitantly results in an increase in kinase activity.
PP1 dephosphorylates pThr288 in vitro
The observation that okadaic acid treatment greatly increases the amount of T288 phosphorylation of Aurora2 suggests that a serine/threonine phosphatase may be also involved in Aurora2 regulation. Genetic evidence relevant to this point has been provided by the analysis of ipl1 mutants of Saccharomyces cerevisiae, where the ipl1 mutant phenotype was found to be opposed by glc7, a mutant of the catalytic subunit of the yeast protein phosphatase1 (Francisco et al., 1994) . Such results correlate well with our observation of an increase in Aurora2 kinase activity only in cells treated with 500 nM okadaic acid, a concentration considered to inhibit both PP1 and PP2A (Figure 1a ). To directly investigate the possibility of Aurora2 being a substrate of PP1 in vitro, we incubated phosphorylated GST-Aurora fusion proteins (generated by PKA in vitro kinase assay) with puri®ed protein phosphatase1 in an in vitro phosphatase assay. The T288 phospho-speci®c antibody recognizes GST-2-KM incubated with the PKA kinase (Figure 4a , upper panel) but following incubation with the PP1 phosphatase the signal disappeared (Figure 4a , lower panel). Thus, PP1 can dephosphorylate the Thr288 residue in Aurora2 in vitro. To test for selectivity we (a) In vitro kinase assays were performed using 1 mg of puri®ed baculovirus expressed recombinant enzyme of wild-type (wt) Aurora2 or the mutant forms T288D, T288A and T287A/T288A. The values of three independent experiments were obtained using a phosphor imaging system and are shown as n-fold increase of activity of the mutant forms versus the wild-type Aurora2 kinase. (b) SF9 cells infected with wild-type virus, or the mutant forms T288D, T288A and T287A/T288A were incubated with or without okadaic acid for 1 h prior to harvest. The Aurora2 enzymes were puri®ed and in vitro kinase assays were performed as described above. The average values of two independent experiments are shown as n-fold increase of kinase activity of okadaic acid treated cells (black bars) versus untreated cells (white bars) investigated whether Aurora2 is the substrate of another phosphatase by performing in vitro phosphatase reactions with radiolabeled GST-Aurora2 fusion proteins as substrates and puri®ed PP1 and PP2A as enzymes (Figure 4b, upper panel) . We chose PP1 (lane 2) and PP2A (lane 3) since they are both inhibited by okadaic acid. We observed a signi®cant reduction in phosphorylation of Aurora2 in the reaction containing PP1 (lane 2). The reduction by half indicates that PP1 may dephosphorylate only one of the two PKA phosphorylation sites. To examine which site was dephosphorylated by PP1, we performed an immunoblot with the phospho-T288 speci®c antibody ( Figure  4b, middle panel) . No Aurora2 protein phosphorylated on T288 could be detected after PP1 treatment indicating that PP1 speci®cally dephosphorylates T288 Figure 3 The cAMP dependent kinase phosphorylates Aurora2 in vitro. (a) In vitro kinase assays were performed using the puri®ed enzymes PKA (lanes 1 and 2), PKC (lanes 3 and 4), Cdc2 (lanes 5 and 6) and ERK2 (lanes 7 and 8) with GST-Aurora2 fusion proteins as substrates. Either 1 mg of the inactive K161M mutant (lanes 1, 3, 5, 7) or the inactive double K161M/T288D mutant (lanes 2, 4, 6, 8) were used. In the top panel reactions were incubated with [ 32 P]g-ATP, in the middle panel non-radioactive reactions were immunoblotted using the phospho-T288 speci®c antibody after separation by SDS ± PAGE. The same membrane was reprobed using an Aurora2 antibody to demonstrate equal input of substrate (bottom panel). (b) Aurora2 wild-type (lanes 1, 2) , the T287A/ T288A double mutant form (lanes 3, 4) or no Aurora2 protein as control (lanes 5, 6) were incubated in the absence (lanes 1, 3, 5) or presence (lanes 2, 4, 6) of PKA enzyme followed by anti-Aurora2 immunoblot analysis (upper panel), or anti-pT288 immunoblot (middle panel). Aurora2 immunoprecipitations were washed three times to remove PKA and subjected to an in vitro kinase assay using myelin basic protein as substrate (lower panel) or an anti-PKAc immunoblot was performed to control for remaining PKA enzyme (bottom panel). (c) Aurora2 immunoprecipitations were incubated with PKA enzyme, washed and subjected to an in vitro kinase assay using myelin basic protein as substrate in the presence or absence of a peptide PKA-Inhibitor. The graph shows the fold induction of Aurora2 kinase activity in an in vitro kinase assay in the presence of PKA-Inhibitor of the PKA phosphorylation sites. Whilst there was a modest reduction in phosphorylation with PP2A overall, it does not appear to aect phosphorylation of T288.
Aurora2 phosphorylation on Thr288 is cell cycle dependent
Our experiments have established that Aurora2 is regulated by phosphorylation of T288 in vitro. To demonstrate that these observations are physiologically relevant we next wished to determine whether T288 phosphorylation of Aurora2 could be observed during the cell cycle in vivo. HeLa cells were arrested in G1 phase by performing a double thymidine block and subsequently released into the cell cycle. The progression of the cell cycle over 12 h was monitored by FACS analysis of propidium iodide stained cells ( Figure 5, bottom panel) , and the cell lysates were subjected to immunoblot analysis using the phospho T288 speci®c Aurora2 antibody and a C-terminal Aurora2 antibody ( Figure 5, top panel) . As shown previously by others, Aurora2 is most abundant in the G2/M phase, between 8 ± 10 h after release (Bischo et al., 1998) . T288 phosphorylated Aurora2 could be detected in vivo and furthermore, appeared to be cell cycle regulated. T288 phosphorylated Aurora2 accumulated as cells were released from the G1-block and progressed towards mitosis. Surprisingly as total levels of Aurora2 accumulated during mitosis, the levels of T288 phosphorylated Aurora2 dropped precipitously, and remained at this low level until cells re-entered G1 phase at 12 h.
The same pattern of regulation was observed in CEM cells fractionated into distinct cell cycle phases by centrifugal elutriation (data not shown). There are several hypotheses possible to explain this observation. Firstly, Aurora2 may be phosphorylated less extensively on T288 during mitosis because PKA activity or the activity of another kinase, which is able to phosphorylate Aurora2 in vivo, is reduced during mitosis. Conversely, PPI activity, or the activity of another phosphatase using Aurora2 as a substrate might be increased during mitosis. Neither of these models is consistent with the requirement of T288 phosphorylation for activation. Another possibility is that the highly active, phosphorylated Aurora2 is extremely unstable and that levels are tightly controlled by degradation during mitosis. There is evidence to support this later hypothesis since each human Aurora family member has a potential destruction box motif at the far C-terminus (RxxLxxV) and in addition Aurora2 contains a KEN-box, a recently described motif suggested to mediate degradation (P¯eger and Kirschner, 2000) . The physical association of Aurora2 with Figure 4 The protein phosphatase 1 dephosphorylates Aurora2 in vitro. (a) GST-Aurora2 K161M fusion proteins (lanes 1, 2) or GST-Aurora2-K161M-T288D fusion proteins (lanes 3, 4) were used as a substrate in in vitro kinase assays with PKA as enzyme (lanes 1 ± 4). The phosphorylated GST fusion proteins were then washed and some samples were incubated with the protein phosphatase 1 (PP1) (lanes 2, 4). An immunoblot analysis was performed with the phospho-T288 speci®c antibody. (b) Using the catalytically inactive GST-2-KM fusion protein as substrate radioactive (top panel) and non-radioactive kinase reactions using PKA as enzyme were performed. The GST-fusion proteins were then incubated with or without a phosphatase. The amount of phosphorylation was determined by phosphor imager. Nonradioactive reactions were subjected to immunoblot analysis with the phospho-T288 speci®c antibody (middle panel) and rehybridized with an Aurora2 antibody (bottom panel). PP1 (lane 2), PP2A (lane 3) Figure 5 Phosphorylation of Aurora2 is cell cycle dependent. HeLa cells were arrested in G1 phase by double thymidine block (0 h) and released into the cell cycle over 12 h. The DNA content of the propidium iodide stained cells monitoring progression through the cell cycle was determined by FACS analysis (bottom panel). Cells were lysed and immunoblot analyses performed with the anti-Aurora2 antibody (top panel) or the phospho-T288 speci®c antibody (middle panel) Cdc20 (Farruggio et al., 1999) , a regulator of the anaphase-promoting complex (APC), further suggests a potential role for the APC in the destruction of Aurora2.
Aurora2 is degraded during mitosis
To determine whether Aurora2 is degraded during mitosis, we looked at the eect of LLnL, a proteasome inhibitor, on the levels of Aurora2 protein. We used asynchronous cells or cells synchronized in G2/M by nocodazole treatment. Cells were released from nocodazole arrest in the presence or absence of LLnL or staurosporine and samples were taken for analysis at 2.5 h. LLnL is a cysteine protease inhibitor shown to prevent degradation of cyclin B during mitosis. Since the actions of LLnL will also induce a mitotic arrest, we used staurosporine, a non-speci®c protein kinase inhibitor, to control for consequences of mitotic arrest versus proteasome inhibition. Protein levels were analysed by immunoblotting ( Figure 6 , left panel). The progression through the cell cycle was monitored by propidium iodide staining and FACS analysis (right panel). We observed signi®cantly elevated Aurora2 protein levels in the cells arrested with nocodazole, that upon release decreased rapidly. The presence of LLnL prevented this decline suggesting that Aurora2 is degraded by a proteasome complex. Release in the presence of staurosporine had no eect indicating that merely mitotic arrest is not sucient for Aurora2 degradation. The same pattern was observed with Cyclin B levels ( Figure 6 ), a well-known substrate of the APC serving as a positive control. Cdc2, not believed to be a substrate of the APC, did not show an increase after LLnL treatment. This experiment provides evidence that Aurora2 is targeted for degradation during mitosis. Interestingly, in immunoblots using the T288 phospho-speci®c antibody little increase was observed after nocodazole treatment, but a signi®cant accumulation of Thr288 phosphorylated Aurora2 was detected after LLnL treatment. Thus, Aurora2 is degraded in a proteaseome-dependent manner during mitosis and Aurora2 phosphorylated on Thr288 appears to be a preferred substrate for degradation.
Aurora2 is target for ubiquitination
Proteins that are degraded in a cell cycle dependent manner during mitosis are most likely substrates of the anaphase-promoting complex. The APC is a multimeric ubiquitin ligase and responsible for ubiquitindependent proteolysis of key regulatory proteins during mitosis. Therefore, potential substrates of the APC should be ubiquitinated. To determine whether ubiquitination of Aurora2 occurred we treated cells with the very potent proteasome inhibitor LLnL, or its less potent analog ALLM, and other drugs as controls. 
Discussion
Our experiments clearly demonstrate a role for phosphorylation in the regulation of Aurora2 activity. We show for the ®rst time that the threonine 288 residue in the catalytic domain of Aurora2 is phosphorylated in vivo. Experiments in vitro suggest that this phosphorylation yields a signi®cantly more active enzyme. Comparison of the amino acid sequence of Aurora2 to that of Cdk2 and other kinases revealed that the T288 residue lies within the activation loop of the enzyme, between the highly conserved motifs DFG and PPE of subdomainVII and VIII typical for serine/threonine kinases. The T288 residue of Aurora2 is the equivalent of the T160 residue in the catalytic domain of Cdk2 (Jerey et al., 1995) . Phosphorylation of Cdk2 on residue T160 causes a considerable increase in Cdk activity towards the classical substrate, histone H1 (Morgan, 1996) . Phosphorylation of the equivalent residue in the cAMP dependent kinase (T197) is shown to be sucient for PKA activation after dissociation of the regulatory component (Knighton et al., 1991) . Aurora2 thus appears to share this common mechanism of activation with other kinases. Interestingly Aurora2 is the only kinase examined so far (see Figure 1b) which has two adjacent threonine residues in the activation loop. Whilst our data strongly support a physiological role for T288 phosphorylation in Aurora2 activity, the relevance of T287 regulation remains to be determined.
We and others have shown that the level of Aurora2 protein peaks during G2/M-phase of the human cell cycle. Due to the diculty in synchronizing mammalian cells suciently and the lack of marker proteins for the dierent stages of mitosis in humans, it is not possible to specify the exact timepoint of highest expression during mitosis by immunoblot analysis however it appears to mirror the pattern seen for cyclin B (data not shown). The phosphorylation of Aurora2 is also cell cycle regulated with T288 phosphorylated Aurora2 accumulating as cells progress towards mitosis providing further evidence for the physiological relevance of this site. We show that both PKA and PKC are able to phosphorylate Aurora2 in vitro, but only PKA can speci®cally phosphorylate residue T288 in vitro. These results are consistent with the ®nding that T288 resides in a PKA consensus motif. We also tested ERK2, Cdc2 and Cdk7 (data not shown) as enzymes that might activate Aurora2, but none of these were able to phosphorylate Aurora2 at detectable levels. PKA activity oscillates during mitosis in Xenopus egg extracts with the lowest level of activity at the onset of mitosis and rising PKA activity during metaphase, peaking at early interphase (Grieco et al., 1996) . We therefore conclude that PKA might be a candidate for the kinase that phosphorylates Aurora2 in vivo, however our data does not exclude the possibility that a related kinase responsible for Aurora2 activation may exist.
Whilst the accumulation of T288 phosphorylated Aurora2 was consistent with published reports of the timing of activation of Aurora2 (Bischo et al., 1998) , we were surprised to observe that during mitosis, when Aurora2 is activated, our ability to detect T288 phosphorylated Aurora2 was severely diminished. Taken together with our in vitro results, it would appear that phosphorylation of T288 is extremely labile, either via dephosphorylation or through degradation. We show that Aurora2 is regulated by phosphatases and that the protein phosphatase 1 can dephosphorylate T288 in vitro. Interestingly, reported that glc7-10, a PP1 mutant in Saccharomyces cerevisiae, induces mitotic arrest and that Ndc10p, a component of the kinetochore complex, is hyperphosphorylated in glc7-10 extracts. In yeast Glc7 functions at G2/M just prior to anaphase (Bloecher and Tatchell, 1999) . In mammalian cells microinjection of anti-PP1 antibodies causes mitotic arrest (Fernandez et al., 1992) . Therefore, PP1 appears to be a good candidate to dephosphorylate T288 during mitosis.
Our data also provide evidence that Aurora2 is degraded during mitosis. This degradation is sensitive to proteasome inhibition and T288 phosphorylated Aurora2 appears to be the preferential substrate for degradation. Unfortunately okadaic acid treatment, which results in this dramatic increase in T288 phosphorylation, appears to also activate an inhibitor of mitotic proteolysis (Vorlaufer and Peters, 1998) which might explain why we observe no alteration in protein level of Aurora2 (Figure 1a, lane 5) . The degradation of Aurora2 is supported ®rstly by the presence of a destruction box motif at the very Cterminus and a KEN box motif at the N-terminus of the protein and secondly by the physical association of Aurora2 with CDC20, an activator of the anaphase promoting complex believed to target potential substrates for ubiquitination by the APC (Farruggio et al., 1999) . Thus, our results are consistent with a model for APC mediated degradation of Aurora2 during mitosis. It will be interesting to explore the mechanism underlying induction of degradation of Aurora2 at the moment of activation during mitosis.
Aurora2 is believed to play a key role in mitosis, maybe by aecting centrosome function and chromosome segregation. Given the pivotal role this enzyme may play in the cell cycle, tight regulation by phosphorylation, dephosphorylation and degradation events is likely to be critical. It will be important to establish how these regulatory processes are modulated in normal and cancer cells.
Materials and methods
Cell culture, cell cycle synchronization and drug treatment HeLa cells were cultured in Dulbecco's modi®ed Eagle's medium with 10% heat-inactivated fetal calf serum, 100 mg of streptomycin per ml and 100 units of penicillin per ml. HeLaS3 cells grew in suspension in minimum essential medium for suspension cultures (Cellgro) with 10% fetal calf serum and penicillin/streptomycin as described above. SF9 insect cells were cultured in SF-900 II SFM (GibcoBRL) at room temperature. To synchronize HeLaS3 cells in G1/S phase a double thymidine block was performed. Exponentially growing cells were incubated for 12 h in DMEM plus 10% FCS in the presence of 2 mM thymidine (Sigma). Cells were released from the ®rst thymidine block by being washed twice with PBS and incubated in fresh medium for 16 h followed by a second incubation with 2 mM thymidine for an additional 12 ± 14 h. To arrest cells at G2/M phase exponentially growing cells were incubated overnight in the presence of 400 ng/ml nocodazole (Calbiochem). To inhibit protein serine/threonine phosphatases Hela cells were treated with 500 nM okadaic acid (Calbiochem) for 1 h unless stated otherwise. Staurosporine, a protein kinase inhibitor, was used at a concentration of 100 ng/ml (Calbiochem). HeLa cells were incubated in the presence of 50 mM of the protease inhibitors LLnL (N-acetyl-Leu-Leu-Norleucinal) or ALLM (N-acetyl-Leu-Leu-Methional) for 2 h to inhibit protein degradation by the proteasome complex (Sigma).
Antibodies
We generated rabbit polyclonal Aurora2 antibodies directed against the C-terminal 13 amino acids (H-CKPSNCQNKE-SASKQS-OH) of the protein. Furthermore we generated rabbit polyclonal antibodies directed against a peptide containing the phosphorylated T288 residue: H-PSSRRTpT-LCGTLD-OH. The rabbit bleeds were anity puri®ed using peptide-coupled columns. The C-terminal Aurora2 antibody recognizes speci®cally Aurora2 in immunoprecipitations, Western blot analyses and immuno¯uorescence, whilst the phospho-T288 antibody recognizes the phosphorylated Aurora2 epitope only in Western blots. The mouse monoclonal antibodies UB (P1A6), cyclin B1 (GNS1), and cdc2p34 (clone 17) as well as the rabbit polyclonal antibody raised against the catalytic subunit of PKA (C-20) were purchased from Santa Cruz Biotechnology. The sheep antimouse antibodies conjugated to horseradish peroxidase (HRP) and the HRP-labeled Protein A were purchased from Amersham Pharmacia Biotech.
Cell lysis, immunoprecipitation and immunoblotting
Cells were lysed in lysis buer (10 mM HEPES buer pH 7.7, 150 mM NaCl, 20 mM b-glycerolphosphate, 5 mM EGTA, 1% NP-40) containing protease inhibitors (protease inhibitor cocktail tablets-complete, Boehringer Mannheim). The lysates were cleared by centrifugation (15 000 g, 25 min at 48C). Lysates for immunoprecipitations were precleared by incubation with Staphylococcus Aureus proteins (Zysorbin, Zymed Laboratories, Inc.) for 15 min on ice. Lysate protein concentrations were measured by the Bio-Rad Protein Assay. For kinase assays 100 mg of cell lysate were incubated with 2 mg Aurora2 antibody for 1 ± 2 h at 48C. To detect ubiquitinated forms of Aurora2 500 mg of cell lysate was used. Immune complexes were collected with 50 ml of protein A/G sepharose slurry and washed three times with 1 ml lysis buer. Proteins were resolved by SDS-polyacrylamide gel electrophoresis (PAGE) using NOVEX Tris-Glycine gels and transferred to Immobilon-P membranes (Millipore Corporation). Residual binding sites on the membranes were blocked with blocking buer (TBS, 0.1% Tween 20, 2% bovine serum albumin). The primary and the secondary antibodies were incubated for 2 h at room temperature. The antibodies were diluted according to the manufacturer's recommendation in blocking buer. Our Aurora2 antibody and the phospho-T288 antibody were diluted to a concentration of 2 mg/ml in blocking buer. The horseradish peroxidase-conjugated secondary antibodies were detected by enhanced chemiluminescence (ECL; Amersham Pharmacia Biotech) and exposed to Kodak-Biomax MR ®lm. To block the antibodies the peptides were added at a concentration of 0.2 mg/ml. When immunoblot analyses were used to quantify the protein concentration of Aurora2 in the baculovirus puri®ed enzyme preparations alkaline phosphatase conjugated secondary antibodies were used for enhanced chemi¯uorescent detection (ECF; Amersham Pharmacia Biotech). Using a Molecular Dynamics Storm 860 imaging system the membranes were scanned and the protein concentrations in each lane could be quanti®ed.
Site-directed mutagenesis
Site-directed mutageneses of human Aurora2 (wild-type and the catalytically inactive K161M mutant) in pcDNA3 were performed using the QuikChange TM Site-Directed Mutagenesis Kit according to the manufacturer's protocol (Stratagene). The T288D Aurora2 mutant was generated using the oligonucleotide primer #1 5'-gctccatcttccaggaggaccgatctctgtggcaccc-3' and primer #2 5'-gggtgccacagagatcggtcctcctggaagatggagc-3'. The T288A Aurora2 mutant was generated using the primer #1 5'-gctccatcttccaggaggaccgcactctgtggcaccc-3' and primer #2 5'-gggtgccacagagtgcggtcctcctggaagatggagc-3' and the T287A/T288A double mutant using the primer #1 5'-gctccatcttccaggagggccgctctctgtggcaccc-3' and the primer #2 5'-gggtgccacagagagcggccctcctggaagatggagc-3'. The presence of these mutations were con®rmed by DNA sequencing of the Aurora2 cDNA.
Expression and purification of Aurora2 from baculovirus infected Sf9 cells
The full-length Aurora2 coding sequence was cloned into pFASTBac HTb (GIBCO BRL, Life Technologies) using standard molecular biology techniques. Baculovirus expressing Aurora2 was obtained by transfection of bacmid DNA into SF9 insect cells according to the manufacturer's instructions (Bac-to-Bac Baculovirus Expression System, GIBCO BRL, Life Technologies). Ampli®ed and titered virus was used to infect SF9 cells at a multiplicity of infection (MOI) of 10. After 48 h SF9 cells were harvested and recombinant protein was puri®ed as follows: Cell pellets were lysed on ice in a buer containing 20 mM b-glycerophosphate, 10 mM HEPES pH 7.7, 5 mM EGTA, 150 mM NaCl and 1% NP40 containing protease inhibitors (Protease inhibitor cocktail tablets`complete'; Boehringer Mannheim). After centrifugation at 48C for 15 min at 10 000 g the supernatant containing the recombinant Aurora2 with its Nterminal His-tag was incubated with Ni 2+ agarose beads (Qiagen) for 30 min at 48C while shaking. Beads were washed ®ve times with 20 volumes of ice-cold wash buer (20 mM bglycerophosphate, 10 mM HEPES pH 7.7, 5 mM EGTA, 250 mM NaCl, 25 mM imidazole, 0.1% NP40, protease inhibitors) before elution of the recombinant protein at RT in small volumes of elution buer (20 mM b-glycerophosphate, 10 mM HEPES pH 7.7, 150 mM NaCl, 250 mM imidazole). Fractions containing the puri®ed, recombinant Aurora2 protein were pooled and dialysed against 1000 volumes of dialysis buer (10 mM HEPES pH 7.7, 150 mM NaCl, 1 mM DTT, 10% glycerol) O/N at 48C. Protein concentration was determined using the Coomassie Plus Protein Assay Reagent Kit (Pierce) according to the manufacturer's recommendations.
Expression and purification of glutathione S-transferase (GST) fusion proteins
To generate GST-Aurora2 fusion constructs, full-length Aurora2 cDNA sequences were ampli®ed by polymerase chain reaction (PCR) using oligonucleotide primers that contained BamHI or NotI restriction sites to facilitate insertion of the ampli®ed fragments into BamHI/NotI linearized pGEX-4T-1 vector (Amersham Pharmacia Biotech). 5'-primer: 5'ggatccttggaccgatctaaagaa-3'; 3'-primer: 5'-ggccgccctggctcaaggatttct-3'. pGEX-Aurora2 constructs were transformed in competent cells of the protease-de®cient Escherichia coli strain BL21 (Stratagene) and the GST-fusion proteins were puri®ed using Glutathione Sepharose beads as described elsewhere (Walter et al., 1999) .
In vitro kinase assays
The in vitro kinase assays were performed in kinase buer (20 mM HEPES buer pH 7.7, 25 mM NaCl, 10 mM MgCl 2 , 1 mM EGTA, 1 mM Dithiothreitol) containing 10 mCi [g-32 P]-ATP and 10 mg myelin basic protein (MBP) or 1 mg GSTfusion proteins as substrates. The reactions were incubated for 10 min at 308C and stopped by adding 26SDS-loading dye. The reactions were separated on Novex 4-20% Trisglycine gels, ®xed for 20 min in 25% isopropanol, 10% acetic acid and dried on a vacuum gel dryer for 45 min at 708C. To determine the degree of substrate phosphorylation the gels were exposed to Kodak-Biomax XR ®lms or to a Kodak phosphor screen and subsequently quanti®ed by scanning with a Storm 860 imaging system (Molecular Dynamics). As enzymes either endogenous Aurora2 immunoprecipitated from 100 mg of cell lysate or 1 mg of recombinant puri®ed His-tagged Aurora2 or ERK2 proteins were used. Protein kinase A (catalytic subunit) (Upstate Biotechnology), protein kinase C (Upstate Biotechnology) or human recombinant cdc2 kinase (Promega) were used as recommended by the manufacturer. The PKA-Inhibitor (Promega) was used at a concentration of 1 mg/kinase reaction.
In vitro phosphatase assays
First in vitro kinase assays were performed using GSTAurora2 fusion proteins coupled to glutathione sepharose beads with ATP or [g-32 P]-ATP. The beads were washed three times with lysis buer to remove the PKA enzyme and a fourth time with phosphatase buer (50 mM Imidazole pH 7.5, 10 mM DTT, 5 mM EDTA). The substrates coupled on beads were incubated for 45 min at room temperature with 0.25 Units of protein phosphatase-1 or protein phosphatase 2A (Upstate Biotechnology). The reactions were stopped by adding 26SDS-loading dye and separated by SDS ± PAGE. The gels were ®xed, dried and exposed as described above in the in vitro kinase assay protocol.
Propidium iodide staining and FACS
Cells were washed and the cell pellets were suspended in 0.5 ml PBS without Ca 2+ and Mg
2+
. To ®x the cells 10 ml of 95% ethanol were added and incubated at 48C for at least 15 min. Cells were washed with PBS supplemented with 1% serum and incubated for 30 min at 378C in 1 ml staining solution (PBS, 1% serum, 0.01 mg/ml propidium iodide (PI) and 0.25 mg/ml RNAseA). The cellular DNA content was analysed with a¯ow cytometer.
